JAC Advance Access published online on February 10, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki016
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Infectious Diseases Department, University of Genoa School of Medicine, San Martino Hospital, Genoa, Italy
* To whom correspondence should be addressed. Objectives: To investigate the clinical efficacy and safety of linezolid in the treatment of Gram-positive prosthetic hip and knee infections. Materials and methods: A retrospective evaluation of patients hospitalized in the Department of Infectious Diseases of San Martino Hospital in Genoa with the diagnosis of Gram-positive prosthetic joint infection and treated with intravenous and/or oral linezolid. Primary end points were the patient clinical outcome at the end of treatment and at long-term follow-up (up to 12 months after the end of treatment). Results: Between May 1999 and September 2003, 20 patients with prosthetic joint infection were treated with linezolid. Pathogens isolated were: methicillin-resistant Staphylococcus aureus (MRSA), 14 strains; methicillin-resistant coagulase-negative staphylococci, five strains; and Enterococcus spp., one strain. The overall duration of treatment was 7.2 ± 2 weeks (range 6-10 weeks). Patients were given intravenous therapy for 3-7 days as inpatients, then were changed as outpatients to oral therapy under weekly laboratory testing. At long-term follow-up (1 year), we observed four cases of failure due to relapsing infections. The other 16 patients treated with linezolid did not need further surgical substitution of prosthesis or surgical joint revision. Linezolid was well tolerated, and no drug-related events leading to discontinuation of treatment were recorded. Conclusions: Our data indicate that linezolid may be an effective alternative therapy for orthopaedic infections caused by Gram-positive resistant pathogens and that a prospective and comparative evaluation of linezolid in this setting is necessary.
Received July 16, 2004
Revised November 24, 2004
Accepted December 9, 2004
Brief report
Linezolid in the treatment of Gram-positive prosthetic joint infections
2 Orthopaedic Department, University of Genoa School of Medicine, Genoa, Italy
Matteo Bassetti, E-mail: mattba{at}tin.it
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Murillo, C. Garrigos, M. E. Pachon, G. Euba, R. Verdaguer, C. Cabellos, J. Cabo, F. Gudiol, and J. Ariza Efficacy of High Doses of Daptomycin versus Alternative Therapies against Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4252 - 4257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K. Gould, R. Brindle, P. R. Chadwick, A. P. Fraise, S. Hill, D. Nathwani, G. L. Ridgway, M. J. Spry, R. E. Warren, and on behalf of the MRSA Working Party of the British Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom J. Antimicrob. Chemother., May 1, 2009; 63(5): 849 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore Future directions with daptomycin J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii41 - iii49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Walls, S. J. Roche, A. O'Rourke, and J. P. McCabe Surgical site infection with methicillin-resistant Staphylococcus aureus after primary total hip replacement J Bone Joint Surg Br, March 1, 2008; 90-B(3): 292 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Soriano, M. Ortega, S. Garcia, G. Penarroja, A. Bove, M. Marcos, J. C. Martinez, J. A. Martinez, and J. Mensa Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2559 - 2563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Gemmell, D. I. Edwards, A. P. Fraise, F. K. Gould, G. L. Ridgway, R. E. Warren, and on behalf of the Joint Working Party of the Britis Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK J. Antimicrob. Chemother., April 1, 2006; 57(4): 589 - 608. [Abstract] [Full Text] [PDF]
|
|